GSK welcomes key agreement to support global preparedness against pandemic influenza

GlaxoSmithKlineGlaxoSmithKline (GSK) welcomes the agreement reached at the Open Ended Working Group (OEWG) coordinated by the World Health Organisation (WHO) on a Framework to support global preparedness for a future influenza pandemic. The agreement establishes the principles of an improved process for influenza virus and benefit-sharing between the WHO GISN (Global Influenza Surveillance Network) and industry.

The agreement will mean that companies supplying vaccines, antivirals and diagnostics for influenza will become key stakeholders in the WHO GISN, which tracks the development and movement of influenza viruses globally. Industry will increase its financial contribution to the GISN to enable the network's geographical expansion and support technical improvements that will accelerate the start of vaccine production, enabling industry to deliver seasonal and pandemic influenza vaccines more quickly.

Industry has also committed to provide other benefits to enable the world's poorer countries to manage the challenge of pandemic influenza. These benefits include real-time production allocations of pandemic vaccines and antivirals, which will be donated to WHO for use, especially for lower-income countries, or supplied at tiered prices, again especially for lower-income countries. In addition, manufacturers have agreed to explore, where appropriate, the establishment of local manufacture of these products in developing countries through technology transfer and licensing.

Andrew Witty, CEO of GSK, said: "This Framework agreement is a critical step in ensuring that the world, including developing countries, is able to prepare properly and equitably for any future pandemic. I applaud the leadership of the WHO. Member States and industry have demonstrated a shared commitment to addressing global needs and an ability to work together and compromise.

"GSK made a significant contribution to managing the previous H1N1 pandemic - through donation of both vaccines and antiviral medicines, and through supplying products to the developing world at tiered prices that reflect ability to pay. We are committed to playing a major role now in preparing for a future pandemic.

"The principles in the agreement strike an important balance. They ensure that there will be equitable access to vaccines and medicines - but maintain an intellectual property framework that will encourage the development of new medicines and vaccines. They also recognise that all stakeholders have their part to play. We look forward to participating in future discussions to move beyond principles and agree a full and balanced plan."

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Most Popular Now

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...